Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. BridgeBio Pharma Inc shares valued at $841,183 were purchased by ANDREA ELLIS on Aug 05 ’25. At $49.00 per share, ANDREA ELLIS acquired 17,167 shares.
Also, Kumar Neil sold 40,000 shares, netting a total of over 1,709,050 in proceeds. Following the sale of shares at $42.73 each, the insider now holds 955,686 shares.
Before that, Kumar Neil had sold 40,000 shares from its account. In a trade valued at $1,701,400, the Chief Executive Officer traded BridgeBio Pharma Inc shares for $42.54 each. Upon closing the transaction, the insider’s holdings decreased to 40,000 shares, worth approximately $43.72 million.
Analysts at Truist started covering the stock with ‘”a Buy”‘ outlook in a report released in late July. As of July 14, 2025, Jefferies has initiated its “Buy” rating for BBIO. Earlier on July 09, 2025, Oppenheimer upgraded its rating. Their new recommendation was “an Outperform” for BBIO stock which previously was a “a Perform”.
Analyzing BBIO Stock Performance
On last trading session, BridgeBio Pharma Inc [NASDAQ: BBIO] plunged -8.94% to $44.81. The stock’s lowest price that day was $42.0901, but it reached a high of $45.85 in the same session. During the last five days, there has been a drop of approximately -1.78%. Over the course of the year, BridgeBio Pharma Inc shares have jumped approximately 71.16%.
Is BridgeBio Pharma Inc subject to short interest?
Stocks of BridgeBio Pharma Inc saw a sharp steep in short interest on 2025-07-15 dropping by -1.64 million shares to 19.48 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 21.12 million shares. A decline of -8.44% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.61 of the overall float, the days-to-cover ratio (short ratio) decline to 5.61.
Which companies own the most shares of BridgeBio Pharma Inc (BBIO)?
In terms of BridgeBio Pharma Inc share price expectations, FactSet research, analysts set an average price target of 72 in the next 12 months, up nearly 46.31% from the previous closing price of $49.21. Analysts anticipate BridgeBio Pharma Inc stock to reach 72 by 2025, with the lowest price target being 72. In spite of this, 9 analysts ranked BridgeBio Pharma Inc stock as Buy at the end of 2025. On June 17, 2025, Wolfe Research assigned a price target of “an Outperform” to the stock and initiated coverage with a $49.
